Lannett (LCIN) : 0.32
52w: 0.32 – 3.72
Shares Outstanding 10.77M
Float 8.39M
Q2 Business and Financial Highlights:
• Net Sales were $80.9 Million
• Gross Margin was 18%, Adjusted Gross Margin was 19%
• Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters
• $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31st
Pipeline Updates:
• Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
• Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year
• Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval
• Generic FLOVENT® DISKUS® ANDA Filing Anticipated by Mid Year
Apr 19, 2023 0.6500 0.7196 0.6501 0.6855 0.6855 280,660
Apr 18, 2023 0.6530 0.6829 0.6530 0.6600 0.6600 30,585
Apr 17, 2023 0.7000 0.7000 0.6525 0.6525 0.6525 39,745
Apr 14, 2023 0.6400 0.7200 0.6375 0.6900 0.6900 129,657
Apr 13, 2023 0.6400 0.6960 0.6400 0.6700 0.6700 60,850
Apr 12, 2023 0.7600 0.7700 0.6600 0.6620 0.6620 126,490
Apr 11, 2023 0.9400 0.9478 0.7200 0.7221 0.7221 185,385
Apr 10, 2023 0.9750 0.9800 0.9067 0.9179 0.9179 30,979
Apr 06, 2023 0.9400 0.9500 0.9100 0.9205 0.9205 72,475
Apr 05, 2023 0.9800 0.9975 0.9300 0.9539 0.9539 312,304
Apr 04, 2023 1.8500 1.8500 0.8600 0.9700 0.9700 982,984
Apr 03, 2023 1.6800 1.8900 1.6800 1.8700 1.8700 25,574
